Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea
- 22 December 2008
- journal article
- research article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 83 (1) , 106-116
- https://doi.org/10.1016/j.diabres.2008.10.009
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetesCurrent Medical Research and Opinion, 2008
- Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trialsCurrent Medical Research and Opinion, 2008
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes, Obesity and Metabolism, 2007
- A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapiesCurrent Medical Research and Opinion, 2007
- Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetesCurrent Medical Research and Opinion, 2007
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia, 2006
- Incretin hormones and insulin sensitivityTrends in Endocrinology & Metabolism, 2005
- Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?Expert Opinion on Investigational Drugs, 2004
- Global and societal implications of the diabetes epidemicNature, 2001
- Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumEuropean Journal of Biochemistry, 1993